# A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

> **NCT06875960** · PHASE4 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 35 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

## Interventions

- **DRUG:** BMS-986165

## Key facts

- **NCT ID:** NCT06875960
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06875960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06875960, "A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06875960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*